Breaking News
FONT-SIZE Plus   Neg
Share SHARE

CVC, ValueAct Continue To Consider Options For Misys - Update

Funds advised by CVC Capital Partners Limited and ValueAct Capital Master Fund, L.P. continue to consider their options with regard to banking software maker Misys Plc (MSY.L, MUSJF.PK), which earlier in the day announced an agreement to be acquired by an investment vehicle owned by US-based private equity firm Vista Equity Partners for 350 pence per share.

Misys had several suitors, including a joint bid from CVC Capital Partners Ltd. and ValueAct Capital, the largest shareholder in Misys. The company's talks with Switzerland-based rival Temenos Group AG ended last week as the parties couldn't agree on the final terms of a transaction.

The current offer price represents a premium of 7.5 per cent to the closing price of its shares on February 2, the last business day prior to the announcement of discussions between Misys and Temenos regarding a possible combination. The deal is estimated to have a total value of about 1.3 billion pounds ($2.1 billion).

An independent committee of Misys directors has unanimously agreed to recommend that Misys shareholders vote in favor of the deal.

Established in 1979, Misys has presence in Europe, the US, Asia, the Middle East and Africa. It serves over 1,300 customers, including all of the world's top 50 banks. Its solutions enable customers to cut costs, manage risk, meet regulatory requirements and realize competitive advantages.

CVC and ValueAct together are exploring options including a possible recommended joint cash offer for the company, a statement said today. They urged Misys shareholders to take no action at this time.

"However, there can be no certainty that an offer will be made by CVC and ValueAct, nor, if made, that a transaction will result,"the statement added.

MSY.L is currently trading at 355.90 pence, up 26.40 pence or 8.01 percent, on a volume of 16.61 million shares compared to a 3-month average volume of 2.92 million shares.

Register
To receive FREE breaking news email alerts for Misys plc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.